Jessica Hagen
The company began trading on the NYSE today under the ticker symbol HNGE, opening at $39.25, up 23% from its IPO price of $32, and closing at $37.56 per share.
MedGemma, built on Gemma 3, aims to help developers build AI-based healthcare applications with open models, including multimodal and text-only versions.
The AI-powered COPD care coordination tool uses EHR data and natural language processing to identify and manage high-risk patients.
AI-powered value-based behavioral health company Ontrak and generative AI radiology workflow company Rad AI also garnered investments.
The tech giant will offer access to the LLM for enterprise use as regulatory scrutiny mounts over the model’s data practices and medical diagnostic claims.
The behavioral health-focused company will use the Series A funds to accelerate product development and expand support for its customer base.
The company offers an at-home test where a breath sample is collected and analyzed by trained dogs and AI to detect early-stage cancer.
The offering measures AI's real-world performance and safety around handling realistic medical conversations, using physician-created rubrics and GPT-4.1 scoring.
The company uses AI and ML to assist biopharma companies with clinical trials and will use the funds to expand its precision medicine and clinical development tools.
The company's filing comes two months after fellow digital musculoskeletal care company Hinge Health filed for IPO.